Fungal Eye Infection Companies

Latest Fungal Eye Infection Companies Update

Dec 2023Novartis AG Received FDA approval for their Vibrence® (natamycin) for ophthalmic suspension, offering a broader treatment option for fungal keratitis with its shorter dosing regimen.Partnered with ophthalmic research centers to develop novel diagnostic tools and therapeutic approaches for improved FK management.

Allergan plc (now part of AbbVie) Completed the sale of their ophthalmology assets to Bausch Health Companies Inc., including their popular antifungal medication Voriconazole for ophthalmic use.BHC is expected to continue development and distribution of Voriconazole, offering patients another treatment option for FK.

Santen Pharmaceutical Co. Launched their EMULSIFY® (amphotericin B) liposomal emulsion in new markets, expanding access to this effective option for severe FK cases.Collaborated with healthcare providers to optimize FK treatment guidelines and raise awareness about early diagnosis and intervention.

Aravind Eye Care System Initiated a randomized controlled trial to investigate the efficacy of collagen cross-linking with topical antifungal therapy for improved visual outcomes in FK patients.Focused on exploring innovative techniques and treatment combinations for enhanced FK management.

Prasad Eye Institute Completed Phase 2/Phase 3 clinical trials on their combination therapy of 5% natamycin and 1% voriconazole for FK, with positive results paving the way for future drug development.Committed to advancing research and development of affordable and effective options for treating FK, particularly in resource-limited settings.

• Allergan Inc.


• Abbott


• Merck & Co., Inc.


• Bayer AG


• Astellas Pharma, Inc.


• GlaxoSmithKline plc


• Sigma-Aldrich


• Novartis AG


• Pfizer, Inc.


• Enzon Pharmaceuticals


• Alcon Laboratories Inc.


• Johnson & Johnson Ltd.